Here is what I have on LAG-3:
2014: How to make anti-PD1 work better with a new player...LAG-3????
2016: The Future for Melanoma Treatment = Combo's! Dr. Weber breaks it down -
Now, there's this ~ anti-LAG-3 with Nivo:
43 melanoma patients with progression on or after treatment with anti-PD-1 or anti-PD-L1, 30 of whom had also been previously treated with ipi - were treated with nivo and BMS-986016 (anti-LAG-3). In the end, 31 patients were evaluated. ORR = 16%. DCR (disease control rate) = 45% "with benefit observed even in some patients refractory to prior anti-PD-1". Median treatment duration = 10 weeks.
Small numbers. Patients who had already been through a lot. Fingers crossed. - c